The development of the EORTC QLQ-C15-PAL: A shortened questionnaire for cancer patients in palliative careMogens Grøenvold, Jakob Bue Bjørner, Morten Aagaard Petersen et al.|European Journal of Cancer|2005Cited by 687
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialHugo Ford, Janet Dunn, Andrea Marshall et al.|The Lancet Oncology|2013Cited by 604
Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancerRN Whistance, Jane Blazeby, Thierry Conroy et al.|European Journal of Cancer|2009Cited by 452
Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancerJane Blazeby, Derek Alderson, Thierry Conroy et al.|European Journal of Cancer|2003Cited by 415
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trialDavid Cunningham, Ruth E. Langley, Sally Stenning et al.|The Lancet Oncology|2017Cited by 286